NASDAQ:SLNO

Soleno Therapeutics Stock Forecast, Price & News

$1.15
0.00 (0.00 %)
(As of 06/11/2021 12:00 AM ET)
Add
Compare
Today's Range
$1.13
$1.17
50-Day Range
$0.97
$1.32
52-Week Range
$0.93
$3.36
Volume1.04 million shs
Average Volume2.51 million shs
Market Capitalization$91.68 million
P/E RatioN/A
Dividend YieldN/A
Beta0.43
30 days | 90 days | 365 days | Advanced Chart
Receive SLNO News and Ratings via Email

Sign-up to receive the latest news and ratings for Soleno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Soleno Therapeutics logo

About Soleno Therapeutics

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics has collaboration with Vanderbilt University to discover and develop next generation K(ATP) channel activators for the treatment of rare diseases. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.89 out of 5 stars

Medical Sector

130th out of 2,096 stocks

Electromedical Equipment Industry

4th out of 62 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Soleno Therapeutics (NASDAQ:SLNO) Frequently Asked Questions

Is Soleno Therapeutics a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Soleno Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Soleno Therapeutics stock.
View analyst ratings for Soleno Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Soleno Therapeutics?

Wall Street analysts have given Soleno Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Soleno Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Soleno Therapeutics?

Soleno Therapeutics saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 3,800,000 shares, an increase of 36.2% from the May 13th total of 2,790,000 shares. Based on an average daily volume of 3,560,000 shares, the days-to-cover ratio is presently 1.1 days. Approximately 7.3% of the company's stock are short sold.
View Soleno Therapeutics' Short Interest
.

When is Soleno Therapeutics' next earnings date?

Soleno Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Soleno Therapeutics
.

How were Soleno Therapeutics' earnings last quarter?

Soleno Therapeutics, Inc. (NASDAQ:SLNO) announced its quarterly earnings data on Wednesday, May, 5th. The company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of ($0.08) by $0.03.
View Soleno Therapeutics' earnings history
.

How has Soleno Therapeutics' stock been impacted by COVID-19?

Soleno Therapeutics' stock was trading at $2.51 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, SLNO shares have decreased by 54.2% and is now trading at $1.15.
View which stocks have been most impacted by COVID-19
.

When did Soleno Therapeutics' stock split? How did Soleno Therapeutics' stock split work?

Soleno Therapeutics shares reverse split on the morning of Friday, October 6th 2017. The 1-5 reverse split was announced on Thursday, October 5th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, October 5th 2017. An investor that had 100 shares of Soleno Therapeutics stock prior to the reverse split would have 20 shares after the split.

What price target have analysts set for SLNO?

2 analysts have issued 12-month target prices for Soleno Therapeutics' shares. Their forecasts range from $8.00 to $8.00. On average, they anticipate Soleno Therapeutics' stock price to reach $8.00 in the next twelve months. This suggests a possible upside of 595.7% from the stock's current price.
View analysts' price targets for Soleno Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Soleno Therapeutics' key executives?

Soleno Therapeutics' management team includes the following people:
  • Dr. Anish Bhatnagar, Pres, CEO, COO & Director (Age 51, Pay $756k)
  • Mr. James H. MacKaness, Chief Financial Officer (Age 57, Pay $198.99k)
  • Mr. Anthony Wondka, Sr. VP & GM (Age 59)
  • Dr. Neil M. Cowen M.B.A., Ph.D., MBA, Sr. VP of Drug Devel.

Who are some of Soleno Therapeutics' key competitors?

What other stocks do shareholders of Soleno Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Soleno Therapeutics investors own include Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), SCYNEXIS (SCYX), OPKO Health (OPK), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Miragen Therapeutics (MGEN), Vaxart (VXRT), Dynavax Technologies (DVAX) and TherapeuticsMD (TXMD).

What is Soleno Therapeutics' stock symbol?

Soleno Therapeutics trades on the NASDAQ under the ticker symbol "SLNO."

Who are Soleno Therapeutics' major shareholders?

Soleno Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Nantahala Capital Management LLC (9.80%), BlackRock Inc. (3.74%), Oracle Investment Management Inc. (2.67%), Geode Capital Management LLC (1.04%), Northern Trust Corp (0.76%) and AWM Investment Company Inc. (0.63%). Company insiders that own Soleno Therapeutics stock include Andrew Sinclair, Gwen A Melincoff, Jack W Schuler, Larry N Feinberg, Ventures Fund V LP Vivo, Vivo Ventures V, Llc and William G Harris.
View institutional ownership trends for Soleno Therapeutics
.

Which institutional investors are selling Soleno Therapeutics stock?

SLNO stock was sold by a variety of institutional investors in the last quarter, including Oracle Investment Management Inc., AWM Investment Company Inc., Silverarc Capital Management LLC, Northern Trust Corp, Nantahala Capital Management LLC, Greylin Investment Mangement Inc., Nuveen Asset Management LLC, and Goldman Sachs Group Inc..
View insider buying and selling activity for Soleno Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Soleno Therapeutics stock?

SLNO stock was acquired by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Oppenheimer & Co. Inc., Geode Capital Management LLC, Clayton Partners LLC, Clayton Partners LLC, BlackRock Inc., Barclays PLC, and Warberg Asset Management LLC. Company insiders that have bought Soleno Therapeutics stock in the last two years include Andrew Sinclair, Gwen A Melincoff, Jack W Schuler, and Larry N Feinberg.
View insider buying and selling activity for Soleno Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Soleno Therapeutics?

Shares of SLNO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Soleno Therapeutics' stock price today?

One share of SLNO stock can currently be purchased for approximately $1.15.

How much money does Soleno Therapeutics make?

Soleno Therapeutics has a market capitalization of $91.68 million. The company earns $-24,640,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Soleno Therapeutics have?

Soleno Therapeutics employs 17 workers across the globe.

What is Soleno Therapeutics' official website?

The official website for Soleno Therapeutics is www.soleno.life.

Where are Soleno Therapeutics' headquarters?

Soleno Therapeutics is headquartered at 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065.

How can I contact Soleno Therapeutics?

Soleno Therapeutics' mailing address is 203 REDWOOD SHORES PARKWAY SUITE 500, REDWOOD CITY CA, 94065. The company can be reached via phone at 650-213-8444 or via email at [email protected]


This page was last updated on 6/12/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.